Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Edgardo S Santos & Lowell Hart. (2020) Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. OncoTargets and Therapy 13, pages 9305-9321.
Read now
Read now
Zi-Yi Xu & Jun-Ling Li. (2019) Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. OncoTargets and Therapy 12, pages 5467-5484.
Read now
Read now
Shun Lu. (2019) Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. OncoTargets and Therapy 12, pages 1521-1538.
Read now
Read now
Marco Tagliamento, Carlo Genova, Erika Rijavec, Giovanni Rossi, Federica Biello, Maria Giovanna Dal Bello, Angela Alama, Simona Coco, Simona Boccardo & Francesco Grossi. (2018) Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opinion on Pharmacotherapy 19:18, pages 2055-2062.
Read now
Read now
Shun Lu, Wei Li, Caicun Zhou, Cheng-Ping Hu, Shukui Qin, Gang Cheng, Jifeng Feng, Jie Wang, Agnieszka Cseh, Barbara Peil, Neil Gibson, Eva Ehrnrooth & Li Zhang. (2018) Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. OncoTargets and Therapy 11, pages 8565-8573.
Read now
Read now
Tiziana Vavalà. (2017) Role of afatinib in the treatment of advanced lung squamous cell carcinoma. Clinical Pharmacology: Advances and Applications 9, pages 147-157.
Read now
Read now
Articles from other publishers (20)
Sara V. Ochoa, Zulma Casas, Sonia L. Albarracín, Jhon Jairo Sutachan & Yolima P. Torres. (2023) Therapeutic potential of TRPM8 channels in cancer treatment. Frontiers in Pharmacology 14.
Crossref
Crossref
Lei Pan, Fanqi Meng, Wei Wang, Xu-hao Wang, Hui Shen, Pengchen Bao, Jian Kang & Delei Kong. (2023) Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Frontiers in Immunology 13.
Crossref
Crossref
Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva & Irina A. Men'shikova. (2022) The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis. Journal of Modern Oncology 24:3, pages 340-344.
Crossref
Crossref
Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, Zhiyi Xue, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Yi-Long Wu & Jie Wang. (2022)
Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with
EGFR
m+ non-small-cell lung cancer
. Future Oncology 18:12, pages 1485-1497.
Crossref
Crossref
Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B. J. Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou & Yi-Long Wu. (2022) A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Targeted Oncology 17:1, pages 1-13.
Crossref
Crossref
Yu-Wei Fang & Chieh-Yu Liu. (2021) Determining Risk Factors Associated with Depression and Anxiety in Young Lung Cancer Patients: A Novel Optimization Algorithm. Medicina 57:4, pages 340.
Crossref
Crossref
Noemi Reguart & Roxana Reyes. (2021) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib. Oncology & Haematology 17:1, pages 36.
Crossref
Crossref
Yueyu Fang, Hui Sun, Yi Chen, Nanyuan Jiang, Lianhua Ji & Junfeng Shi. (2021) A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient. Medicine 100:31, pages e26801.
Crossref
Crossref
Mengyao Sun, Ye Guo, Xu Wang, Chao Sun, Jiangbo Shao, Yinghui Xu, Shi Qiu & Kewei Ma. (2020) Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report. Journal of International Medical Research 48:10, pages 030006052096470.
Crossref
Crossref
Arkadiusz Z. Dudek, Kate Baxstrom, Sushma Bharadwaj, Anne Blaes, Amit Kulkarni, Emil Lou, Vijeyaluxmy Nehru, Emma Rabinovich, Ardaman Shergill & Maya Viner. 2020. Precision Medicine in Oncology. Precision Medicine in Oncology
1
60
.
R Donald Harvey, Val R Adams, Tyler Beardslee & Patrick Medina. (2020)
Afatinib for the treatment of
EGFR
mutation-positive NSCLC: A review of clinical findings
. Journal of Oncology Pharmacy Practice 26:6, pages 1461-1474.
Crossref
Crossref
Abdulaziz B. Hamid & Ruben C. Petreaca. (2020) Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers 12:4, pages 927.
Crossref
Crossref
Hong Jian, Yuchen Han, Yongfeng Yu & Shun Lu. (2019) Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations. Anti-Cancer Drugs 30:8, pages 873-878.
Crossref
Crossref
Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodríguez Abreu, Dolores Isla, Fabrice Barlesi, Olivier Molinier, Jeannick Madelaine, Clarisse Audigier-Valette, Sang-We Kim, Hye Ryun Kim, Mustafa Ozguroglu, Mustafa Erman, Firas Benyamine Badin, Tarek M. Mekhail, Ronald Scheff, Michael J. Chisamore, Behbood Sadrolhefazi & Jonathan W. Riess. (2019) Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer 20:3, pages e407-e412.
Crossref
Crossref
Manoj Kumar Kashyap & Omar Abdel-Rahman. (2018) Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Molecular Cancer 17:1.
Crossref
Crossref
Namita Sharma & Stephen Graziano. (2018) Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. Cancer Treatment Reviews 69, pages 143-151.
Crossref
Crossref
Yuri Taniguchi, Yoko Matsumoto, Ryutaro Furukawa, Sayaka Ohara & Kazuhiro Usui. (2018) The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. International Journal of Clinical Oncology 23:3, pages 452-457.
Crossref
Crossref
Franz Villarroel-Espindola, Xiaoqing Yu, Ila Datar, Nikita Mani, Miguel Sanmamed, Vamsidhar Velcheti, Konstantinos Syrigos, Maria Toki, Hongyu Zhao, Lieping Chen, Roy S. Herbst & Kurt A. Schalper. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer. Clinical Cancer Research 24:7, pages 1562-1573.
Crossref
Crossref
Shicheng Li, Xiao Sun, Shuncheng Miao, Jia Liu & Wenjie Jiao. (2017) Differential protein-coding gene and long noncoding RNA expression in smoking-related lung squamous cell carcinoma. Thoracic Cancer 8:6, pages 672-681.
Crossref
Crossref
Paul Zarogoulidis, Panos Chinelis, Anastasia Athanasiadou, Konstantinos Porpodis, Anastasios Kallianos, Aggeliki Rapti, Georgia Trakada, Lemonia Velentza, Haidong Huang, Theodora Tsiouda & Wolfgang Hohenforst-Schmidt. (2017) “Liquid elbows” due to afatinib administration. Respiratory Medicine Case Reports 22, pages 64-66.
Crossref
Crossref